SYSTEM PROBLEMS:
We are currently experiencing technical problems with content and functionality requiring a login.
We apologize for the inconvience.
- Sort by:
|
<< first | < prev
page:
of 19
|
records per page:
next >
| last >>
|
| pages: 1 2 3 4 5 ... 16 17 18 19
|
presentations:
1 to
50 of
921
|
Session Overview - Hazards Ahead: The Intersection of HIV and Substance Use
Steffanie A. Strathdee
University of California San Diego, San Diego, CA, USA
Trends and Correlates of Methamphetamine Use Among Men Who Have Sex With Men in the US, 2014-2021 (ABSTRACT
999)
Michael P. Barry
University of Washington, Seattle, WA, USA
Changes in HIV PrEP Awareness and Use Among PWID in 19 US Cities, 2018 and 2022 (ABSTRACT
1009)
Patrick Eustaquio
Centers for Disease Control and Prevention, Atlanta, GA, USA
Prescription Opioid Use and Disorder Among Older Adults With HIV in the US From 2008-2019 (ABSTRACT
995)
Stephanie Shiau
Rutgers University, Piscataway, NJ, USA
Hazardous Alcohol Use Predicts Detectable Viremia Among Ugandan Women: A Prospective Analysis (ABSTRACT
1001)
Amanda P. Miller
San Diego State University
Associations of Alcohol Consumption With Long-Term Mortality of ART-Naive Persons Seeking HIV Care (ABSTRACT
1003)
Daniel Fuster
Hospital Germans Trias i Pujol, Barcelona, Spain
Discussion with Audience Questions and Answers
Session Overview - Is the Weight Over: GLP-1 Receptor Agonists Are Here
Todd T. Brown
The Johns Hopkins University, Baltimore, MD, USA
Impact of Semaglutide on Weight Change Among People With HIV: A Stratified Analysis by Baseline BMI (ABSTRACT
797)
Heidi M. Crane
University of Washington, Seattle, WA, USA
Effects of Semaglutide on Inflammation and Immune Activation in HIV-Associated Lipohypertrophy (ABSTRACT
798)
Allison Ross Eckard
Medical University of South Carolina, Charleston, SC, USA
Effects of Semaglutide on Muscle Structure and Function in the SLIM Liver Study (ABSTRACT
799)
Grace L. Ditzenberger
University of Colorado Anschutz Medical Campus, Aurora, CO, USA
Discussion with Audience Questions and Answers
Session Overview - PEP Prevention Toolbox: Do We Know How to Use It?
Sigal Yawetz
Brigham and Women's Hospital, Boston, MA, USA
HIV Post-Exposure Prophylaxis Prescription Trends: United States, 2013-2022 (ABSTRACT
1131)
Mary R. Tanner
Centers for Disease Control and Prevention, Atlanta, GA, USA
BIC/FTC/TAF as HIV PEP Was Well-Tolerated With High Adherence and No Seroconversions (ABSTRACT
1134)
Darrell H. S. Tan
St Michael's Hospital, Toronto, Canada
A Matter of Time: Factors Associated With Delayed nPEP Initiation (ABSTRACT
1130)
Nicholas Brian Bana
ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy
PrEP Following PEP: An Effective HIV Risk-Reduction Strategy (ABSTRACT
1133)
Gary Whitlock
Chelsea and Westminster NHS Foundation Trust, London, UK
Discussion with Audience Questions and Answers
Session Overview - Viral Rebound
Javier Martinez-Picado
IrsiCaixa Institute for AIDS Research, Badalona, Spain
Common T-Cell Features Predicting Time to Rebound in Interventional and Non-Interventional Treatment (ABSTRACT
484)
Tongcui Ma
Gladstone Institutes, San Francisco, CA, USA
The Fraction of HIV Reservoir Variants Neutralized by Autologous IgG Correlates With Time to Rebound (ABSTRACT
482)
Mauro A. Garcia
The Johns Hopkins University, Baltimore, MD, USA
Intact HIV Reservoir Levels Are Stable After Short-Term ART Interruption (ABSTRACT
487)
Prerana Shrestha
Brigham and Women's Hospital, Boston, MA, USA
Dynamics of the Intact HIV Reservoir During ART Following Analytical Treatment Interruption (ABSTRACT
485)
Maegan R. Manning
National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA
Immune Responses and HIV Reservoir Evolution From Pre-ART to 5 Years Into Post-Treatment Control (ABSTRACT
486)
Leah Carrere
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
Discussion with Audience Questions and Answers
Session Overview - Anal Cancer Screening and Pathogenesis
Timothy J. Wilkin
Weill Cornell Medicine, New York, NY, USA
Evaluation of the Performance of Different High-Resolution Anoscopy Triage Strategies in MSM LWH (ABSTRACT
760)
Eugenio Nelson Cavallari
Sapienza University of Rome, Rome, Italy
Anal Self-Sampling Is Suitable for Anal Cancer Screening Among Men Who Have Sex With Men in Togo (ABSTRACT
761)
Charlotte Charpentier
Hôpital Bichat-Claude-Bernard, Paris, France
Clinical Predictors and Outcomes of Anal Cancer for People With HIV in an Inception Cohort (ABSTRACT
759)
Edward Cachay
University of California San Diego, San Diego, CA, USA
Long-Term ART Is Not Associated With Reduced Anogenital Cancer Risk: A Case-Cohort Study (ABSTRACT
762)
Maanasa Mendu
Harvard University, Cambridge, MA, USA
Discussion with Audience Questions and Answers
Session Overview - Hypertension and HIV: Pregnancy, Postpartum, and Beyond
Elizabeth M. Stringer
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
Maternal HIV Is Associated With Lower Risk of Preeclampsia Among Zambian Women (ABSTRACT
913)
Katelyn J. Rittenhouse
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
Hypertension in Pregnant Persons by HIV Status and by DTG vs EFV Use in Botswana (ABSTRACT
910)
Denise L. Jacobson
Harvard University, Cambridge, MA, USA
Association of HIV and Dolutegravir With Changes in Blood Pressure During Pregnancy and Postpartum (ABSTRACT
916)
Jennifer Jao
Northwestern University, Chicago, IL, USA
Pregnancy History Affects Age-Related Comorbidity Burden in US Women With and Without HIV (ABSTRACT
912)
Lauren F. Collins
Emory University, Atlanta, GA, USA
DTG Versus EFV Initiation in Pregnancy Is Not Associated With Postpartum Blood Pressure (ABSTRACT
918)
Thokozile R. Malaba
University of Cape Town, Cape Town, South Africa
Discussion with Audience Questions and Answers
Session Overview - Persistent Immune Activation and Inflammation During Antiretroviral Therapy
Frank Maldarelli
National Cancer Institute, Frederick, MD, USA
Low-Level HIV Viremia Affects T-Cell Activation and Senescence in InSTI Era (ABSTRACT
348)
Violeta Lara Aguilar
Institute of Health Carlos III, Madrid, Spain
Ultra-Low Level HIV p24 Production as a Driver of Immune Activation in Individuals Treated with ART (ABSTRACT
349)
Enrico Richter
Bonn University Hospital, Bonn, Germany
CARD8 Activation in Myeloid Cells as a Driver of Inflammation in HIV Infection (ABSTRACT
350)
Marilia R. Pinzone
Washington University in St Louis, St Louis, MO, USA
Increased Immune Activation Following Acute Sleep Deprivation in People With HIV on ART (ABSTRACT
351)
Bernard J. C. Macatangay
University of Pittsburgh School of Medicine
Immunosuppressive Effects of LLDT-8 in ART-Treated SIV-Infected Rhesus Macaques (ABSTRACT
352)
Xiaosheng Liu
Tsinghua University, Beijing, China
Discussion with Audience Questions and Answers
Session Overview - Violence, Displacement, and HIV
Mesfin Teklu Tessema
International Rescue Committee
Impact of Natural Disasters on HIV Risks and Viral Suppression in Ugandan Fishing Village (ABSTRACT
1205)
Hadijja Nakawooya
Rakai Health Sciences Program, Kalisizo, Uganda
The Need to Address Violence for PrEP Uptake Among Adolescent Girls and Young Women in South Africa (ABSTRACT
1221)
Courtney P. Bonner
RTI International, Research Triangle Park, NC, USA
Prevalence of HIV and Viral Load Suppression Among Refugees in Uganda, October to December 2021 (ABSTRACT
1206)
Jessica E. Justman
Columbia University Medical Center, New York, NY, USA
Violence and HIV Sexual Risk Behaviours Among Adolescent Girls and Young Women: Eswatini Experience (ABSTRACT
1226)
Siphiwe M. Shongwe-Gama
ICAP at Columbia University, Mbabane, Swaziland
|
<< first | < prev
page:
of 19
|
records per page:
next >
| last >>
|
| pages: 1 2 3 4 5 ... 16 17 18 19
|
presentations:
1 to
50 of
921
|
